Rhenman & Partners Asset Management’s Stoke Therapeutics STOK Stock Holding History

Rhenman & Partners Asset Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11M	Sell	64,500 -18,500	-22%	-$594K	0.2%	89
2026 Q1	$2.7M	Sell	83,000 -133,000	-62%	-$4.36M	0.33%	73
2025 Q4	$6.86M	Sell	216,000 -34,000	-14%	-$1.02M	0.64%	56
2025 Q3	$5.88M	Buy	+250,000	New	+$4.28M	0.65%	48

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rhenman & Partners Asset Management's STOK Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Stoke Therapeutics (STOK) stake by 22% in Q2 2026, selling an estimated $594K and leaving 64,500 shares worth $2.11M. The position accounts for 0.2% of the portfolio, ranked #89.

Rhenman & Partners Asset Management first reported a position in STOK in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.86M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Rhenman & Partners Asset Management held 64,500 shares of Stoke Therapeutics worth $2.11M as of Q2 2026.
Rhenman & Partners Asset Management sold 18,500 Stoke Therapeutics shares in Q2 2026, an estimated $594K.
Stoke Therapeutics made up 0.2% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #89 holding.
Rhenman & Partners Asset Management first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 4 quarters since.
Rhenman & Partners Asset Management's Stoke Therapeutics position peaked at $6.86M in Q4 2025.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.